Navigation Links
AcelRx Pharmaceuticals Appoints Mark G. Edwards To Its Board of Directors
Date:9/28/2011

REDWOOD CITY, Calif., Sept. 28, 2011 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc., (NASDAQ: ACRX) ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, announced that Mark G. Edwards has joined its Board of Directors.  Mr. Edwards will also serve as the chairman of the Audit Committee.  Mr. Edwards founded Deloitte Recap LLC (formerly, Recombinant Capital, Inc. "Recap"), a pharmaceutical and biotechnology consulting company, in 1988, and served as its Managing Director until the end of 2010.  Recap has provided analysis, advice and negotiation support concerning the structure and valuation of biopharmaceutical alliances to several hundred companies over the past two decades.  From 1999 until December 2000, Mr. Edwards was a General Partner of International Biomedicine Management Partners. He also served as a Director of Allos Therapeutics, Inc. from 1999 until 2007.  Mr. Edwards has a Bachelor's Degree in Economics and an MBA, both from Stanford University.

"Mark brings a wealth of both financial and pharmaceutical industry partnering transaction experience to AcelRx," noted Richard King, AcelRx President and Chief Executive Officer. "We are pleased to have Mark join the Board of Directors and to chair our Audit Committee."

"I am excited to join the AcelRx Board," stated Mr. Edwards.  "AcelRx has developed an impressive pipeline of market-focused pain product candidates.  I am convinced of the tremendous opportunity afforded by the AcelRx sufentanil NanoTab technology in treating both post-operative pain and other acute and breakthrough pain conditions."  

About AcelRx Pharmaceuticals, Inc.

Based in Redwood City, CA, AcelRx Pharmaceuticals, Inc. (Nasdaq:

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AcelRx Pharmaceuticals to Present at Two Healthcare Investor Conferences in the Second Half of September
2. AcelRx Pharmaceuticals to Present at the Rodman & Renshaw Global Investment Conference
3. AcelRx Pharmaceuticals to Present at the Canaccord Genuity Growth Conference
4. AcelRx Pharmaceuticals Reports First Quarter 2011 Financial Results
5. AcelRx European Patent Covering its NanoTab® Sublingual Delivery Technology for Acute and Breakthrough Pain Pipeline Products Emerges From Opposition Period
6. AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
7. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
8. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
9. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
10. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
11. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: ... CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation ... receipt of $385,642, net of transaction costs, in ... Technology Business Tax Certificate Transfer Program sponsored by ...
(Date:1/22/2015)... CLEVELAND , Jan. 22, 2015  ViewRay™, a privately ... entered into an exclusive distributor agreement with ITOCHU Corporation ... radiation therapy system for the treatment of cancer in ... (me-rid-i-an) system, is the world,s first and only MRI-guided ...
(Date:1/22/2015)...  Amgen (NASDAQ: AMGN ) today announced that it will ... Tuesday, Jan. 27, 2015, after the close of the U.S. financial ... the investment community at 2 p.m. PT. Participating in the call ... chief executive officer, and other members of Amgen,s senior management team. ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... a leading Clinical Research Organization, will exhibit its comprehensive ... for Medical Oncology,s 35th annual congress to be held ... from Medical Affairs, Operations and other departments will be ... successful execution of oncology and hematology trials. ...
... 8 Concentric Medical, Inc. today announced the ... utilizing Stentriever™ technology for clot retrieval in ischemic ... offering in a portfolio of products from Concentric ... acute ischemic stroke. The Trevo,s stent-like design leverages ...
Cached Medicine Technology:PRA International to Exhibit at European Oncology Congress 2Concentric Medical Announces Commercial Launch of Trevo™ in Europe 2Concentric Medical Announces Commercial Launch of Trevo™ in Europe 3
(Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
(Date:1/22/2015)... released a new blog post presenting the basic features of ... an accidental death and dismemberment rider for a car insurance ... benefits if the insured dies in an accident. Accidental death ... insurance. , AD&D is not expensive and can be ...
(Date:1/22/2015)... 2015 Yesterday, Senator Holly Mitchell ... Kristin Olsen (R-Modesto) were honored by the California ... biotechnology, biomedical science, medical device and pharmaceutical innovation ... the “2014 Life Sciences Champion” award from CHI ...
(Date:1/22/2015)... Four years since the release of their debut recording ... marriage of Avasa & Matthew Love – the duo are pleased ... release through White Swan Records on February 24, 2015. , THE ... path available to all of us to walk out of the ...
(Date:1/22/2015)... January 22, 2015 As interest in the ... care gains momentum worldwide, Rev. Eric J. Hall , ... Network (HCCN), will be the keynote speaker on January ... Israel’s public health system. , The conference, “Hope and Resilience: ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... discussions with FDA -, MENLO PARK, Calif., Dec. ... of customizable drug-eluting stent (DES),systems, today announced that it ... for CE Mark approval of its Custom NX DES,System., ... dossier and the,drug formulation submission from Biosensors International Group. ...
... ST. PAUL (December 26, 2007) University of Minnesota ... researchers have discovered a new fast-acting antidote to cyanide ... those who are exposed to the chemical namely ... cyanide antidotes work slowly and are ineffective when administered ...
... hay fever and other allergic reactions, by preventing the ... by scientists. Researchers hope their finding, published today (Thursday ... allow therapies to be developed that treat allergies by ... a gene known as GATA-3 can block the development ...
... Dec. 26 A lot of Americans take advantage ... to lose weight and live,healthier. There may be a ... that work focus on healthy long-term lifestyle changes., ... Registered journalists can access video, audio, text, graphics ...
... cell research to needle exchanges to medical marijuana and ... science, according to a new book by a leading ... Weill Cornell Medical College. , "Truth, Lies, and Public ... Collide" (Praeger Press, 2007) is authored by Dr. Madelon ...
... results are promising, they don,t address benefits of drug ... treatment that wipes out abnormal heart tissue reduces the ... implanted after heart attacks, a new trial showed. , ... it slips into abnormal rhythms, they are desirable to ...
Cached Medicine News:Health News:XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe 2Health News:XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe 3Health News:U of M researchers discover fast-acting cyanide antidote 2Health News:Fight against hay fever and other allergies helped by new immune system discovery 2Health News:Heart Procedure Reduces Need for Defibrillator Shocks 2Health News:Heart Procedure Reduces Need for Defibrillator Shocks 3
Sera available in three levels for the control of accuracy and precision for up to 31 analytes...
Human based material available in two levels for the control of accuracy and precision for upto 23 analytes....
CRP Liquid Conrtols level 3...
The IRN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of iron in serum....
Medicine Products: